Cronos Group Inc. Files 8-K with Material Agreement

Ticker: CRON · Form: 8-K · Filed: 2024-06-25T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, corporate-event

TL;DR

Cronos Group Inc. signed a big deal on June 20th, filing an 8-K. Details in exhibits.

AI Summary

On June 20, 2024, Cronos Group Inc. entered into a material definitive agreement related to its business. The filing also includes other events and financial statements and exhibits. The company is incorporated in British Columbia, Canada, with its principal executive offices in Toronto, Ontario.

Why It Matters

This 8-K filing indicates a significant development for Cronos Group Inc., potentially impacting its operations and financial standing through a new material definitive agreement.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's future performance.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement Cronos Group Inc. entered into?

The filing states that Cronos Group Inc. entered into a material definitive agreement on June 20, 2024, but the specific details of this agreement are not provided in the excerpt. Further information would likely be found in the exhibits.

When was the report filed with the SEC?

The report was filed as of June 25, 2024.

What is Cronos Group Inc.'s former company name?

Cronos Group Inc.'s former company name was PharmaCan Capital Corp., with a date of name change on October 21, 2015.

Where are Cronos Group Inc.'s principal executive offices located?

Cronos Group Inc.'s principal executive offices are located at 111 Peter Street, Suite 300, Toronto, Ontario M5V 2H1.

What is the SIC code for Cronos Group Inc.?

The Standard Industrial Classification (SIC) code for Cronos Group Inc. is 2833, which corresponds to MEDICINAL CHEMICALS & BOTANICAL PRODUCTS.

From the Filing

0001656472-24-000078.txt : 20240625 0001656472-24-000078.hdr.sgml : 20240625 20240625170733 ACCESSION NUMBER: 0001656472-24-000078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240620 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 241069813 BUSINESS ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2H1 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 8-K 1 cron-20240620.htm 8-K cron-20240620 false CRONOS GROUP INC. 0001656472 Toronto Canada 001-38403 Ontario 0001656472 2023-11-08 2023-11-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 CRONOS GROUP INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38403 N/A (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 111 Peter Street, Suite 300 Toronto , Ontario M5V 2H1 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 416 ) 504-0004 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value CRON The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01.    Entry into a Material Definitive Agreement. Credit Agreement On June 20, 2024, Cronos Group Inc. (the “ Company ”) announced that Peace Naturals Project Inc., its wholly owned subsidiary (“ PNP ”), entered into an amended and restated credit agreement (the “ Credit Agreement ”) among Cronos Growing Company Inc. (“ GrowCo ”), as borrower, the lenders from time to time parties thereto and PNP, as administrative agent. The Company previously made available to GrowCo, a joint venture 50% owned by the Company and 5

View on Read The Filing